3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
14
Carcinoma, Non-Small-Cell Lung
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasms
4
Melanoma
4
Lung Neoplasms
4
Leukemia, Myelomonocytic, Chronic
4
Leukemia, Myeloid, Acute
4
Breast Diseases
4
Thoracic Neoplasms
3
Respiratory Tract Neoplasms
3
Lung Diseases
3
Bronchial Neoplasms
3
Uveal Melanoma
2
Sezary Syndrome
2
Rectal Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Pinealoma
2
Pancreatic Neoplasms
2
Neoplasms, Glandular and Epithelial
2
Neoplasms by Histologic Type
2
Myeloproliferative Disorders
2
Myelodysplastic Syndromes
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Large B-Cell, Diffuse
2
Interventions
exemestane
1
entinostat
1
Mammography
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Mammary Neoplasms, Animal
×
entinostat
×
Clear all
NCT00676663
2022-05-11
ENCORE301
Syndax Pharmaceuticals
Phase 2
Completed
130 enrolled
18 charts